Area of research
Infectious Diseases · Neurology
Research interest
Research interests include SARS-CoV-2 and COVID-19 Research, COVID-19 Clinical Research Studies, Long-Term Effects of COVID-19, and SARS-CoV-2 detection and testing.
Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies
Characterisation of Elevenin-Vc1 from the Venom of Conus victoriae: A Structural Analogue of α-Conotoxins
SARS-CoV-2 host-shutoff impacts innate NK cell functions, but antibody-dependent NK activity is strongly activated through non-spike antibodies
A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination
ACE2 expression in adipose tissue is associated with cardio-metabolic risk factors and cell type composition—implications for COVID-19
Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
The effect of spike mutations on SARS-CoV-2 neutralization
Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant
SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity
Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern
The legacy of maternal SARS-CoV-2 infection on the immunology of the neonate
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
Humoral and cellular immunity to delayed second dose of SARS-CoV-2 BNT162b2 mRNA vaccination in patients with cancer
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans
A dynamic COVID-19 immune signature includes associations with poor prognosis
Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection
Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings
Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis
Estimates of the rate of infection and asymptomatic COVID-19 disease in a population sample from SE England
Molecular rationale for antibody-mediated targeting of the hantavirus fusion glycoprotein
Author Correction: A dynamic COVID-19 immune signature includes associations with poor prognosis
A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at the fusion glycoprotein apex